Combining PARP Inhibitor With Immunotherapy-Does the Promise of Preclinical Data Translate to Clinic?

JAMA Oncol. 2023 Jan 1;9(1):25-27. doi: 10.1001/jamaoncol.2022.4591.
No abstract available

Publication types

  • Editorial
  • Comment

MeSH terms

  • Antineoplastic Agents* / pharmacology
  • Humans
  • Immunotherapy / adverse effects
  • Poly(ADP-ribose) Polymerase Inhibitors* / pharmacology
  • Poly(ADP-ribose) Polymerase Inhibitors* / therapeutic use

Substances

  • Poly(ADP-ribose) Polymerase Inhibitors
  • Antineoplastic Agents